ABSTRACT Activated/uninhibited calcineurin is both necessary and sufficient to induce cardiac hypertrophy, a condition that often leads to dilated cardiomyopathy, heart failure, and sudden cardiac death. We expressed constitutively active calcineurin in the adult heart of Drosophila melanogaster and identified enlarged cardiac chamber dimensions and reduced cardiac contractility. In addition, expressing constitutively active calcineurin in the fly heart using the Gal4/UAS system induced an increase in heart wall thickness. We performed a targeted genetic screen for modifiers of calcineurin-induced cardiac enlargement based on previous calcineurin studies in the fly and identified galactokinase as a novel modifier of calcineurin-induced cardiomyopathy. Genomic deficiencies spanning the galactokinase locus, transposable elements that disrupt galactokinase, and cardiac-specific RNAi knockdown of galactokinase suppressed constitutively active calcineurin-induced cardiomyopathy. In addition, in flies expressing constitutively active calcineurin using the Gal4/UAS system, a transposable element in galactokinase suppressed the increase in heart wall thickness. Finally, genetic disruption of galactokinase suppressed calcineurin-induced wing vein abnormalities. Collectively, we generated a model for discovering novel modifiers of calcineurin-induced cardiac enlargement in the fly and identified galactokinase as a previously unknown regulator of calcineurin-induced cardiomyopathy in adult Drosophila.
A CTIVATED/uninhibited calcineurin is both necessary and sufficient to induce cardiac hypertrophy (Molkentin et al. 1998; Wilkins and Molkentin 2002; Van Berlo et al. 2013) . Transgenic mice expressing constitutively active calcineurin (CanA act ) display cardiac hypertrophy (Molkentin et al. 1998) and the genetic or pharmacological inhibition of calcineurin suppresses agonist and pressure overloadinduced cardiac hypertrophy (Sussman et al. 1998; Taigen et al. 2000; Wilkins and Molkentin 2002; Van Berlo et al. 2013) . Prolonged cardiac hypertrophy is a known risk factor for dilated cardiomyopathy, heart failure, and sudden death (Levy et al. 1990; Messerli and Ketelhut 1991; Drazner et al. 2004; George 2013; Grossman and Paulus 2013 ). In contrast, cardiac hypertrophy stimulated by exercise is physiological, is not typically associated with abnormal cardiac function, and does not stimulate calcineurin/nuclear factor of activated T cells (NFAT) signaling , supporting the concept that calcineurin promotes pathological cardiac hypertrophy.
Calcineurin acts as a calcium/calmodulin-dependent protein phosphatase that consists of two subunits: a large CanA subunit (60 kDa) and a small CanB subunit (19 kDa). In the mouse, there are three CanA genes (Ppp3ca, Ppp3cb, and Ppp3cc) and two CanB genes (Ppp3r1 and Ppp3r2); in the fly, there are three CanA genes (CanA1, CanA-14F, and Pp2B-14D) and two CanB genes (CanB and CanB2) (NCBI Gene, http://www.ncbi.nlm.nih.gov/gene). The large CanA subunit has phosphatase activity and consists of several domains: the catalytic domain, which regulates protein dephosphorylation (Klee et al. 1979) ; the CanB binding domain (Klee et al. 1988) ; the calcium/calmodulin binding domain; and the autoinhibitory domain (Shibasaki et al. 2002) . In the inactive state, the autoinhibitory domain inhibits the catalytic domain. Binding of calcium/calmodulin activates calcineurin by alleviating this autoinhibition. A constitutively active calcineurin (CanA act ) is generated by eliminating the autoinhibitory domain and has been used to investigate calcineurin signaling (Molkentin et al. 1998; Sullivan and Rubin 2002; Gajewski et al. 2003) . Expression of CanA act has been found to induce cardiac hypertrophy (Molkentin et al. 1998) , skeletal muscle hypertrophy (Musaro et al. 1999; Semsarian et al. 1999) , and slow twitch skeletal muscle specification (Chin et al. 1998; Wu et al. 2000) . The smaller subunit (CanB) is constitutively bound to CanA and is required for maintaining calcineurin expression (Watanabe et al. 1995; Klee et al. 1998; Parsons et al. 2004) . Deficiency of CanB results in significant cardiomyopathy, including impaired cardiomyocyte growth, impaired contractility, and lethality after birth (Schaeffer et al. 2009; Maillet et al. 2010) .
Calcineurin signaling in mammals involves calcineurindependent dephosphorylation of NFAT transcription factors (Molkentin et al. 1998; Okamura et al. 2000) . In contrast, Drosophila do not have calcineurin-regulated isoforms of NFAT and therefore use NFAT-independent pathways (Keyser et al. 2007) . Myocyte enhancer factor (Mef2) is a well-known NFAT-independent pathway that has been implicated in calcineurin-mediated cardiac and skeletal muscle hypertrophy (Wilkins and Molkentin 2002; Sakuma and Yamaguchi 2010) . Cardiac calcineurin expression has been shown to activate Mef2 reporter activity (Passier et al. 2000) . The expression of a dominant-negative Mef2 inhibited CanA actinduced cardiac enlargement and overexpressing Mef2 caused cardiac chamber dilation (Van Oort et al. 2006) . In skeletal muscle, calcineurin activates Mef2 with exercise (Wu et al. 2001; Sakuma et al. 2008) . Mechanistically, calcineurin was found to co-immunoprecipitate with Mef2 and induce activation of Mef2 through dephosphorylation (Wu et al. 2001) .
Previously, two independent screens were conducted to identify modifiers of calcineurin phenotypes in tissues other than the heart (Sullivan and Rubin 2002; Gajewski et al. 2003) . Sullivan and Rubin (2002) performed a dominant modifier screen in the Drosophila eye and found five suppressor and four enhancer loci. Two modifier genes, CanB2 and sprouty, were identified. However, modifier genes within the seven other broadly mapped loci remained uncharacterized. Gajewski et al. (2003) found seven different deletion intervals that suppressed the lethal phenotype of constitutively active calcineurin driven by the general mesodermal driver 24B. CanB2 was determined to be a modifier and preliminary experiments suggested that Mef2 might be the modifier for another interval. Importantly, only one interval overlapped between these two studies on chromosome 3L, cytolocation 66F.
Many pathways are conserved in mammalian and Drosophila cardiac development (Bodmer and Venkatesh 1998; Cripps and Olson 2002; Zaffran and Frasch 2002; Zaffran et al. 2002) . In fact, strategies based on fly genetics have been used to identify genes that cause or modify cardiomyopathies (Bier and Bodmer 2004; Wessells and Bodmer 2004; Yu et al. 2010) . The Drosophila heart can be efficiently monitored in real time in intact awake Drosophila, using optical coherence tomography (OCT) . Importantly, Drosophila is well adapted for genetic studies: it has a relatively short generation time, welldeveloped genetic manipulation methods, and well-developed genetic resources, including mutation stocks and vectors for making transgenics (Kohler 1994; St. Pierre et al. 2014) . Therefore, we conducted studies using fly genetics to identify novel modifiers of cardiac calcineurin.
We generated Drosophila that expressed CanA act in the heart under the control of the cardiomyocyte-specific driver, tinC (tinC-CanA act ), an approach that is analogous to that in previous studies of transgenic mice (Molkentin et al. 1998) . tinC-CanA act flies had enlarged cardiac chamber dimensions and reduced cardiac contractility. In addition, expressing CanA act in the heart with tinC-Gal4 . UAS-CanA act induced an increase in cardiac wall thickness. Based on the prior genetic screens (Sullivan and Rubin 2002; Gajewski et al. 2003) , we then designed a deficiency screen targeting the overlapping region on chromosome 3L. Here we show that deficiencies in a genetic region encoding galactokinase (Galk) rescued CanA act -induced cardiac enlargement and decreased function. To test the hypothesis that Galk is a novel modifier of calcineurin in the heart, two independent transposable element insertions in Galk and cardiacspecific expression of RNAi directed against Galk were studied. Genetic disruption of Galk rescued the cardiac enlargement phenotype in tinC-CanA act flies and a transposable element insertion in Galk rescued tinC-Gal4 . UAS-CanA actinduced increase in cardiac wall thickness. In addition, genetic disruption of Galk also suppressed an abnormal wing vein phenotype induced by the wing driver e16E-Gal4 . UAS-YCanA act . These findings suggest that galactokinase modifies calcineurin-mediated cardiomyopathy in adult Drosophila.
Materials and Methods

Drosophila stocks
The following Drosophila stocks were obtained from the Bloomington Drosophila Stock Center: w 1118 (Flybase ID: P{hsILMiT}2.4, , P{GAL4-dpp. blk1}40C.6 (dpp-Gal4), P{Act5C-GAL4}25FO1 (Act5C-Gal4), and P{GAL4-Mef2.R}3 (Mef2-Gal4). The double balancer line WR135 was kindly provided by Robin Wharton (Ohio State University, Columbus, OH). The P{tinC-Gal4} line was kindly provided by Manfred Frasch (Mount Sinai Medical School, New York, NY) (Yin and Frasch 1998) . The P{tinC-GFP} (tinC-GFP) line was generated as previously described by inserting the 304-bp tinC genetic sequence into the pGreen-HPelican vector (Yin and Frasch 1998; Barolo et al. 2000; Yu et al. 2010 ) and the construct was injected at the Duke University Model Systems Genomics Facility. The tinC-YCanA act , tinC-FCanA act , and UAS-YCanA act Drosophila lines were generated at the Duke University Model Systems Genomics Facility by injecting the corresponding constructs into Drosophila embryos.
Calcineurin constructs
Constitutively active calcineurin was amplified from the calcineurin gene Pp2B-14D as previously described, using the primers ATG TCT TCG AAT AAC CAG AGC AGC AG (forward) and TCA GTT GCG TAT CAC CTC CTT GCG CA (reverse) (Sullivan and Rubin 2002) . Restriction enzyme sites and Flag-tagged CanA act (FCanA act ) were inserted by extending the N terminus with primers carrying the corresponding sequences. CanA act was amplified in topo vector (Invitrogen, Carlsbad, CA) and inserted at the 39 end to yellow fluorescent protein (YFP) in the pEYFP-C1 vector with appropriate restriction enzyme sites to form YFP-tagged CanA act (YCanA act ). Full-length FCanA act or YCanA act PCR products were subsequently cloned into the pCaSpeR5 Drosophila expression vector, inserting a tinC-hsp70 promoter at the 59 end as previously described (Yin et al. 1997; Yu et al. 2010 ) ( Figure 1A ). The catalytic activity of N-terminal YFP-tagged CanA act has been confirmed in studies by a number of investigators, using well-characterized NFAT reporter assays (Tokoyoda et al. 2000; Burkard et al. 2005) , NFAT phosphorylation assays (Tokoyoda et al. 2000) , and NF-kB reporter assays (Kang et al. 2007 ). The UASYCanA act construct was generated similarly by inserting YFP-tagged CanA act into the pUAST vector following the UAS sequence.
OCT to measure cardiac function in adult Drosophila
End-diastolic dimension and end-systolic dimension in adult Drosophila were measured using OCT (Bioptigen, Durham, NC) as previously described . Briefly, 7-10 days posteclosion, female Drosophila were placed in GelWax medium and allowed to awaken. M-mode images through the conical chamber were collected for immobilized awake Drosophila. End-diastolic and end-systolic dimensions (EDD and ESD, respectively) were measured in ImageJ, calibrated to a 125-mm-thick glass slide. Fractional shortening (FS) is calculated as (end-diastolic dimension 2 end-systolic dimension/end-diastolic dimension) 3 100% and used as a measure of cardiac contractility. All end-systolic dimensions are supplied in Supporting Information, Table S1 , File S1.
Several types of controls were used and compared for our study: w 1118 (Flybase ID: FBst0003605; EDD = 54.10 6 2.95 mm; FS = 98.79 6 1.21%), w 1118 used to create transgenics from the Duke University Model Systems Genetics Facility (Flybase ID: FBst0006326; EDD = 41.53 6 5.08 mm; FS = 99.76 6 1.21%), tinC-Gal4 (EDD = 51.59 6 4.14 mm; FS = 96.70 6 1.53%), tinC-Gal4 heterozygous with w 1118 (EDD = 48.34 6 2.34 mm; FS = 98.92 6 0.74%), tinC-GFP (EDD = 52.88 6 5.85 mm; FS = 98.24 6 1.76%), and tinC-GFP heterozygous with w 1118 (EDD = 56.34 6 4.32 mm; FS = 98.78 6 0.58%). We performed a one-way ANOVA comparing OCT measurements between all control groups and show that none were significantly different from each other ( Figure S1A ).
Histology
Histology was performed according to standard paraffin embedding and hematoxylin and eosin staining procedures for the fly (Ashburner 1989) . Briefly, 3-5 days posteclosion, Drosophila were washed with 70% EtOH before fixing in 10% buffered formalin at 4°overnight. This fixes the hearts at their most relaxed state, end-diastole. To assess this, OCT images were measured and compared between alive w 1118 end-diastolic dimension (46.37 6 4.91 mm, N = 9) and the size of the heart after EtOH fixation (50.19 6 6.09 mm, N = 9), P = NS, Student's t-test. The next day, Drosophila were dehydrated starting with a PBS wash and subsequent alcohol gradient into xylene. Drosophila were then incubated overnight at 60°under vacuum in liquid paraffin wax. Samples were then positioned appropriately in molds and allowed to harden. Consecutive sections (8 mm) were cut using a microtome and adhered to poly-L-lysine-coated glass slides. The slides were subsequently rehydrated into water and stained with hematoxylin and eosin. The slides were brought back through the alcohol gradient and xylene and mounted in Cytoseal XYL mounting medium (Thermo Fisher Scientific). Images were subsequently quantified in ImageJ, calibrated with a hemocytometer grid measuring 50 mm. Locating the position along the cardiac tube for measurement was determined as previously described by examining the portion of the sections where an en face section of the cardiac tube was visible and measuring three sections (24 mm) posterior to this section (Yu et al. 2010) . Wall thickness was calculated as the average of dorsal, ventral, left, and right walls, excluding the dorsal longitudinal muscle underlying the ventral side of the conical chamber.
Minos excision
The Minos insertion in Galk, Mi{ET1}Galk MB10638 , was excised precisely according to standard transposable element excision procedures (Arca et al. 1997; Metaxakis et al. 2005) . Briefly, the Mi{ET1}Galk MB10638 males were crossed to virgin females containing the Minos transposase P{hsIL-MiT}2.4. After 3 days, adult flies were removed, and the embryos were heat-shocked in a 37°water bath for 1 hr for 4 consecutive days. Male progeny were selected for the presence of the Minos insertion and the Minos transposase according to eye color (the Minos element expresses GFP, and Minos transposase expresses a red eye color from miniwhite in the insertion) and crossed to the double balancer fly stock WR135 (Sp/CyO;TM2/MKRS). Male progeny were selected for the absence of GFP and mini-white, indicating a successful excision, and crossed again to WR135 virgin females. Progeny harboring excisions were crossed to each other to make a homozygous stock. These stocks were assayed for the presence of a precise excision, using primers sequencing through the affected genomic region.
qRT-PCR
Drosophila were collected 3-5 days after eclosion and five whole flies were collected or 10-15 fly hearts were dissected for each group. RNA was extracted using RNA-Bee RNA isolation reagent (Amsbio) according to the manufacturer's protocol. SuperScript II (Invitrogen) reverse transcription according to the manufacturer's protocol was followed by real-time PCR analysis, using a predesigned taqman probe for Galk (probe Dm01801608_g1; Applied Biosystems, Foster City, CA).
Tissue-specific phenotypes
For wing vein phenotypes, Drosophila from the respective crosses were collected at 3-5 days after eclosion. The wings were detached using forceps and the ventral surface was placed face down on GelWax plates. The wings were examined for abnormalities under a dissection microscope at 403 or imaged under a Leica M165FC fluorescence stereo microscope equipped with a Leica DFC310FX camera at 503. A range of wing vein abnormalities were observed, which were divided into normal, abnormalities of the posterior crossvein (PCV), or abnormalities of both the PCV and the longitudinal vein 5 (L5). The number of wings under each category of wing vein phenotype was counted for each group and the percentage of total wings counted was calculated. Statistical significance to detect for a rescue of the abnormal wing vein phenotype (pooling the two different types of wing vein abnormalities) with the Df(3L)ED4416 deficiency or Mi{ET1}Galk MB10638 insertion was determined using Fisher's exact test. Tissue-specific expression of CanA act with dpp-Gal4, Act5C-Gal4, and Mef2-Gal4 was analyzed similarly by counting the number of progeny with the respective phenotypes according to the crosses and genotypes described in Figure 6 .
Statistical analysis
All data were analyzed in GraphPad Prism 6 software. Student's t-test was performed for single comparisons and one-way ANOVA and post hoc analysis with Bonferroni correction were conducted for group comparisons. Fisher's exact test was employed to determine the rescue of the proportion of flies displaying wing or lethality phenotypes.
Results
Expression of CanA act in the adult fly heart caused cardiac enlargement
To identify genetic modifiers of cardiac calcineurin, we generated two types of sensitized Drosophila lines expressing CanA act in the heart: (1) CanA act under the direct control of the tinC promoter, a 304-bp intronic region within the tinman gene that controls cardiac-specific gene expression with a minimal hsp70 promoter (tinC-CanA act ) (Yin et al. 1997; Lo and Frasch 2001; , tinC-CanA act transgenic lines were generated under the direct control of the cardiac-specific tinC genomic fragment in the context of an hsp70 minimal promoter to harbor either a flag-or YFPtagged CanA act , FCanA act or YCanA act respectively, Figure  1A ; and (2) CanA act under control of the UAS promoter (UAS-CanA act ) where cardiac-specific CanA act was expressed in Drosophila, using the Gal4/UAS system (tinC-Gal4 . UASCanA act ) (Brand and Perrimon 1993) .
We performed measurements of cardiac chamber dimensions during complete relaxation (end-diastole) and full contraction (end-systole), using OCT ; fractional shortening was calculated as described in Materials and Methods and used as a measurement of cardiac contractility. In agreement with previous studies, w 1118 control Drosophila displayed close to 100% fractional shortening ) ( Figure 1B and Figure S1A ). Drosophila expressing either FCanA act or YCanA act displayed enlarged end-diastolic dimension and reduced fractional shortening ( Figure 1B and Figure S1B ). To account for possible positional effects of the transgene, end-diastolic dimensions in several different lines were tested. tinC-YCanA act or tinC-FCanA act insertions on the first, second, and third chromosomes all induced enlarged end-diastolic dimensions, suggesting that the transgene is causing cardiac enlargement and the phenotype is not due to disruption of an endogenous gene from transgenic insertion ( Figure S1C ). Cardiac enlargement persisted in tinC-CanA act flies compared to controls over 5 weeks of age ( Figure S1D ).
Histological analyses confirmed that the tinC-CanA act fly hearts were significantly larger than controls ( Figure 1C ). The heart wall was significantly thicker in tinC-Gal4 . UASCanA act but not in tinC-CanA act flies ( Figure S1 , E and F). This distinction may be due to augmented CanA act expression with tinC-Gal4 . UAS-CanA act . Immunofluorescence staining and confocal microscopy confirmed the cardiacspecific expression of tinC-CanA act ( Figure S1G ). To determine whether the enlargement in heart size was due to increase in number of cells or increase in cell size, we examined the number of nuclei in tinC-CanA act and tinC-GFP control hearts. Confocal microscopy of tinC-CanA act hearts expressing cardiacspecific nuclear localized RFP showed the same number of cardiomyocytes compared to controls, indicating that the phenotype was not the result of abnormalities in cardiomyocyte number ( Figure S1H ).
A region on chromosome 3L harbored novel modifiers of tinC-CanA act -mediated cardiac enlargement
To test the feasibility of finding a modifier using tinC-CanA act as the sensitized line, we examined the effect of genetic deficiency of the known downstream regulator of calcineurin, Mef2 (Van Oort et al. 2006) . A deficiency in the known calcineurin modifier Mef2 rescued tinC-CanA act -induced cardiac enlargement ( Figure S2 ).
Previous screens identified that a region located at cytolocation 66F rescued 24B-CanA act -induced lethality (Gajewski et al. 2003 ) and corresponded to a suppressor and enhancer region for GMR-CanA act -induced rough eye (Sullivan and Rubin 2002) . Therefore, we reasoned that a deficiency screen covering this region would likely identify a modifier of CanA act -induced cardiomyopathy. Genomic deficiency lines surrounding this region were initially examined for the ability to suppress tinC-CanA act -mediated cardiac enlargement (Figure 2A) . Two lines, Df(3L)ED4416 and Df(3L)BSC130, suppressed tinC-CanA act -induced cardiac enlargement ( Figure 2 , B and C, and Figure S3A ). Excluding the regions in which the deficiencies did not rescue the phenotype, we narrowed the region down to 80 kb that is predicted to encode 13 genes ( Figure 2A ). Of note, Df(3L)ED4421 spans the suppressor region, but exerts a cardiac enlargement phenotype on its own, indicating that genes within this large deficiency induce cardiac dilation independent of CanA act ( Figure S3A ). For this reason, the Df(3L)ED4421 deficiency was not considered when determining the suppressor region.
We validated the suppressor region corresponding to Df(3L)ED4416 and Df(3L)BSC130 by evaluating the cardiac phenotype in tinC-Gal4 . UAS-CanA act Drosophila in the context of these deficiencies. tinC-Gal4 . UAS-CanA act flies displayed cardiac enlargement similar to that of tinC-CanA act flies (Figure 3 ). Genetic disruption of the known calcineurin modifiers Mef2, sty, or CanB2 rescued the fractional shortening of tinC-Gal4 . UAS-CanA act flies ( Figure 3 and Figure  S3B ), demonstrating the fidelity of using a sensitized Drosophila line to find modifiers of calcineurin. Cardiac enlargement (end-diastolic dimension) of tinC-Gal4 . UAS-CanA act hearts was rescued by Df(3L)ED4416 and Df(3L)BSC130 (Figure 3 ). These results suggest that Df(3L)ED4416 and Df(3L)BSC130 harbor modifiers of CanA act -induced cardiac enlargement.
Identification of galactokinase as a novel modifier of calcineurin-induced cardiac enlargement
The refined suppressor region contained a total of 13 genes ( Figure 2A ). Two genes, galactokinase (Galk) and arginine kinase (Argk), have high expression in the adult fly heart (flyatlas.org) (Chintapalli et al. 2007; Robinson et al. 2013) . To determine whether Galk is a modifier of the tinC-CanA act cardiac phenotype, we tested two Drosophila lines that had transposable element insertions in Galk and decreased Galk transcript expression: PBac{PB}Galk c03848 and Mi{ET1}Galk MB10638 . In the context of tinC-CanA act , PBac{PB}Galk c03848 and Mi{ET1}Galk MB10638 rescued the tinC-CanA act -induced decrease in cardiac contractility, and a precise excision of the Mi{ET1}Galk MB10638 insertion, Mi{ET1}Galk rev , reverted this rescue (Figure 4 , A and B, and Figure S3C ). Additionally, cardiac-specific expression of RNAi directed against Galk also rescued tinC-CanA act -induced cardiac enlargement (Figure 4, C and D) . Galk expression levels were reduced in the transposable element insertion and Galk RNAi-expressing flies (Figure 4 , E-G). To test whether the tinC-Gal4 . UAS-YCanA act -induced hypertrophy would be rescued, we examined whether Mi{ET1}Galk MB10638 would prevent the CanA act -induced increase in cardiac wall thickness. Flies expressing tinC-Gal4 . UAS-YCanA act show rescue of the increase in wall thickness ( Figure 4H ). Additionally, tinC-CanA act flies had reduced life span compared to controls, which was rescued in the context of Mi{ET1}Galk MB10638 ( Figure S4 ). These results support the hypothesis that Galk is a modifier of calcineurin in the heart. , and tinC-Flag-tagged CanA act (tinC-FCanA act ). CanA act , constitutively active calcineurin; B, CanB binding domain; M, calmodulin binding domain; I, autoinhibitory domain. tinC is composed of a 304-bp genomic DNA element driving transgene expression in all cells constituting the heart tube as previously described (Yin et al. 1997; Lo and Frasch 2001; . (B) Representative OCT m-mode images and summary data for end-diastolic dimension and fractional shortening of w 1118 control (N = 16) and heterozygous tinC-YCanA act from cross with w 1118 (N = 19) flies. CanA act flies show enlarged end-diastolic dimensions and reduced fractional shortening. (C) Representative transverse paraffin sections of homozygous tinC-GFP control (N = 11) and tinCYCanA act (N = 9) fly hearts (blue arrows indicate the fly heart). Summary data for lumen area and perimeter are shown in micrometers. The tinC-YCanA act fly displayed a significantly enlarged cardiac lumen area and perimeter. (Student's t-test, *P , 0.05, **P , 0.01, ***P , 0.001 compared to either w 1118 or tinC-GFP control. Data represent mean 6 SEM.)
We then tested whether Mi{ET1}Galk MB10638 would rescue a non-calcineurin-mediated cardiomyopathy of the troponin I mutant hdp2 that shows a flight muscle abnormality and cardiac dilation . Mi{ET1}Galk MB10638 did not rescue the cardiac dilation phenotype of heterozygous hdp2 flies ( Figure S5 ), indicating that Galk modification is specific to CanA act -induced cardiomyopathy.
We also tested Argk as a possible modifier for calcineurin. A Drosophila line with an insertion in Argk, PBac{WH}Argk f05525 , had normal cardiac function and did not rescue tinC-CanA actinduced cardiac enlargement ( Figure S6 , A-C).
In addition, the dorsocross genes (Doc1, Doc2, and Doc3) are homologous to mammalian T-box genes and known to regulate embryonic cardiac development (Reim and Frasch 2005) . Accordingly, we examined the effects of these candidate genes on the tinC-CanA act cardiac enlargement phenotype, using OCT. Doc1, Doc2, and Doc3 RNAi lines were obtained and crossed into tinC-Gal4, tinC-CanA act flies to test for rescue of the CanA act phenotype. Genetic disruption of the Doc genes with RNAi did not rescue tinC-CanA act -induced cardiac enlargement ( Figure S6D ). Interestingly, several cardiac-specific RNAi lines directed against the Doc genes caused an enlarged cardiac phenotype on their own ( Figure S6D ).
Tissue-specific suppression of CanA act -induced phenotypes in noncardiac tissues with genetic deficiency of Galk Next, we used a Gal4/UAS system for driving CanA act with noncardiac tissue drivers. The expression of CanA act under Figure 2 Molecularly defined deficiencies Df(3L)ED4416 and Df(3L)BSC130 rescued calcineurin-mediated abnormalities in adult flies. (A) Genetic map of deficiency stocks tested (adapted from Gbrowse, http://flybase. org/cgi-bin/gbrowse/dmel). Dashed lines indicate the suppressor region. Genes within the suppressor region are shown in the magnified view below. (Green bars, rescuing deficiencies; red bars, nonrescuing deficiencies; black bar, deficiency that causes cardiomyopathy on its own.) (B and C) Summary data for (B) end-diastolic dimension and (C) fractional shortening of w 1118 control (first column) tinC-YCanA act alone and in the context of molecularly defined genomic deficiencies. All deficiencies were tested in the heterozygous states. (N = 17-51 for each group.) Two deficiency lines rescued the tinC-YCanA act phenotype, narrowing down the original suppressor region to the region in between the dotted lines in A. Note that Df(3L)ED4421 covers the deficiency region but was dilated on its own without CanA act expression ( Figure S3 ) and was not considered in defining the deficiency region. (One-way ANOVA with Bonferroni correction; *P , 0.05, **P , 0.0001; data represent mean 6 SEM.) control of the engrailed wing driver e16E-Gal4 caused an abnormality in the PCVs and the longitudinal wing vein L5 ( Figure 5 ). Importantly, Df(3L)ED4416 significantly rescued the e16E-Gal4 . UAS-YCanA act -induced abnormal wing vein phenotype. The percentage of flies that had normal wing veins significantly increased from 11 to 44%, and the percentage of flies with abnormal wing vein phenotypes decreased from 89 to 56% with a genetic deficiency encompassing Galk (Figure 5 ). To further investigate the involvement of Galk in wing vein abnormality, the effect of disruption of Galk with a transposable element insertion was examined in e16E-Gal4 . UAS-YCanA act wings. Disruption of Galk with Mi{ET1}Galk MB10638 in e16E-Gal4 . UASYCanA act flies also rescued the wing vein phenotypes, albeit at a lesser rate compared to the deficiency, with the percentage of normal wing vein flies increasing from 5 to 31% and the percentage of abnormal winged flies decreasing from 95 to 69% in the context of Mi{ET1}Galk MB10638 (Figure 5, bottom right) .
Expression of CanA act under control of the ubiquitous driver, Act5C-Gal4, caused larval lethality ( Figure 6A ), while expression under the ectodermal driver, dpp-Gal4, caused a complete inability of the wing to expand ( Figure 6B ), and expression under the muscle driver, Mef2-Gal4, caused lethality at a pupal stage ( Figure 6C ). In contrast to the observed rescue of the abnormal wing vein phenotype, Df(3L)ED4416 was not sufficient to rescue the wing or lethality phenotypes driven by Act5C-Gal4, dpp-Gal4, or Mef2-Gal4, suggesting that deficiency of Galk suppresses CanA act -induced phenotypes in a tissue-specific manner. We also examined the ability of Mi{ET1}Galk MB10638 to suppress the Mef2-Gal4 . UAS-YCanA act lethality phenotype and show that Mi{ET1}Galk MB10638 was not able to rescue the Mef2-Gal4 . UAS-YCanA act -induced lethality ( Figure 6C ), further indicating that Galk may not modify Mef2-Gal4 . UAS-YCanA act -induced lethality.
Discussion
Calcineurin is a known mediator of cardiac hypertrophy in mammalian hearts and understanding the signals that regulate calcineurin has the potential to alter cardiac pathology. Here we show that (1) CanA act in the Drosophila heart induced cardiac enlargement and reduced cardiac contractility; (2) Galk disruption suppressed the CanA actmediated cardiac enlargement, increase in wall thickness, and posterior wing vein phenotypes; and (3) Galk regulation of CanA act -induced phenotypes was tissue specific. Using the resources that are available in fly genetics, the ability to phenotype in vivo cardiac chamber sizes, and the unique fact that flies lack calcineurin-regulated NFAT, we identified a potential new regulator of calcineurin in the Drosophila heart. We also observed that CanA act induced sustained cardiac enlargement in Drosophila during aging and reduced life span. Furthermore, known regulators of calcineurin signaling, including Mef2, rescued the observed cardiac abnormalities, supporting our hypothesis that these Figure 3 tinC-Gal4 . UAS-CanA act displayed cardiac enlargement that was rescued by tinC-CanA act -rescuing deficiencies and diminished contractility phenotype that was rescued by known calcineurin modifiers. (A and B) Summary data for (A) end-diastolic dimension and (B) fractional shortening of w 1118 controls (N = 9); tinC-Gal4 . UASYCanA act (N = 32) alone; heterozygous tinC-Gal4 (N = 7); and tinC-Gal4 . UAS-YCanA act in the presence of Mef2 (N = 11), sty (N = 12), CanB2 (N = 23), Df(3L)ED4416 (N = 18), and Df(3L)BSC130 (N = 13). All transgenes and mutations were heterozygous. Known modifiers of calcineurin signaling, Mef2, sty, and CanB2, rescued tinC-Gal4 . UASYCanA act cardiac contractility (sty rescued fractional shortening but not end-diastolic dimension). In addition, the tinCYCanA act -rescuing deficiencies Df(3L)ED4416 and Df(3L) BSC130 also rescued tinC-Gal4 . UAS-YCanA act cardiac enlargement [Df(3L)BSC130 rescued end-diastolic dimension but not fractional shortening]. (*P , 0.05, **P , 0.01, ***P , 0.0001; one-way ANOVA with Bonferroni correction; data represent mean 6 SEM.)
approaches can identify modifiers of calcineurin-mediated cardiac abnormalities.
Two prior screens of the fly scored changes in eye morphology or lethality caused by activated calcineurin and identified several genomic regions that harbor potential modifiers. Four enhancer regions and five suppressor regions were identified in a mutagenesis screen of the fly eye (Sullivan and Rubin 2002) , whereas seven suppressor regions were discovered in a deficiency screen for lethality (Gajewski et al. 2003) . These studies identified cytological regions in the fly genome Figure 4 Genetic disruption of Galk rescued tinC-CanA actinduced reduction in cardiac contractility and tinC-Gal4 . UAS-CanA act -induced hypertrophy. (A and B) Summary data for (A) end-diastolic dimension and (B) fractional shortening of flies expressing w 1118 control, tinC-YCanA act , the transposable elements PBac{PB}Galk c03848 , Mi{ET1}Galk MB10638 , or precise excision of Mi{ET1}Galk MB10638 (Mi{ET1}Galk rev ), in the context of tinC-YCanA act . The two transposable elements in Galk rescued tinC-YCanA act -mediated cardiac contractility (fractional shortening), while a precise excision reverted the rescue. [(A) *P , 0.05, **P , 0.01; (B) *P , 0.05, **P , 0.001, ***P , 0.0001 compared to tinC-YCanA act or Mi{ET1}Galk MB10638 as indicated with an overbar; N = 14-27 for each group; one-way ANOVA with Bonferroni correction for multiple comparisons, all data represent mean 6 SEM.] (C and D) Summary data for (C) enddiastolic dimension and (D) fractional shortening of w 1118 control, CanA act only, UAS-Galk no driver (heterozygous with w 1118 ), tinC-Gal4 driver only (heterozygous with w 1118 ), Galk RNAi only flies, and flies expressing tinC-YCanA act in the context of cardiac Galk RNAi. RNAi to Galk significantly rescued tinC-YCanA act -mediated cardiac enlargement. (*P , 0.01, **P , 0.0001 compared to tinC-YCanA act ; N = 7-20 for each group; one-way ANOVA with Bonferroni correction for multiple comparisons, all data represent mean 6 SEM.) (E) qRT-PCR for Galk expression of w 1118 control, homozygous PBac{PB}Galk c03848 , or homozygous Mi{ET1}Galk MB10638 . Galk expression is downregulated by transposable element insertions. (*P , 0.001 compared to w 1118 control; N = 3 in each group; one-way ANOVA with Bonferroni correction for multiple comparisons, all data represent mean 6 SEM.) (F) qRT-PCR of Galk expression in w 1118 control flies, flies heterozygous for tinC-YCanA act alone, and flies in the context of heterozygous Mi{ET1}Galk MB10638 or a precise excision of Mi{ET1}Galk MB10638 , Mi{ET1}Galk rev . (*P , 0.05, **P , 0.001 compared to heterozygous tinC-YCanA act / Mi{ET1}Galk MB10638 ; N = 8 in each group; one-way ANOVA with Bonferroni correction for multiple comparisons, all data represent mean 6 SEM.) (G) Galk expression for tinC-Gal4 heterozygous with w 1118 (driver only) and heterozygous UAS-Galk RNAi knockdown with a tinC-Gal4 driver (Galk RNAi). Galk expression is downregulated by transposable element insertions. (N = 3 for each group; Student's t-test *P , 0.001, Galk RNAi vs. tinC-Gal4 driver only.) (H) Representative hematoxylin-and eosin-stained histological sections and quantification of wall thickness for heterozygous tinC-Gal4 (from cross with w 1118 , N = 8), tinC-Gal4 . UAS-YCanA act (N = 13), or tinC-Gal4 . UAS-YCanA act in the context of Mi{ET1}Galk MB10638 (N = 6). tinC-Gal4 . UAS-YCanA act caused a cardiac hypertrophy phenotype that was rescued by Mi{ET1}Galk MB10638 . Blue arrowheads point to the heart. *P , 0.05, one-way ANOVA with Bonferroni correction, all data represent mean 6 SEM. (All transgenes were heterozygous unless otherwise noted.) and, based on these important findings, we focused our attention on a region that was common to both studies but lacked identification of the candidate modifier of calcineurin. Using molecularly defined genomic deficiencies, transposable element insertions, precise excisions, and transgenic RNAi, we identified that galactokinase was a candidate modifier of calcineurin-mediated cardiac abnormalities in the fly. Galactokinase may function either as an enhancer of calcineurin signaling or in a pathway downstream of calcineurin activation. Interestingly, previous studies have not implicated an interaction between calcineurin and galactokinase.
Our results demonstrate that deficiency of Mef2 suppressed cardiac-CanA act -induced cardiac enlargement. Since Drosophila do not express calcineurin-regulated NFAT, this implies that Mef2 functions independent of NFAT in our system. In agreement with our results, studies in skeletal muscle and C 2 C 12 myogenic cells have shown that calcineurin binds to Mef2, leading to hypophosphorylation and enhanced transcription activity (Wu et al. 2000 (Wu et al. , 2001 . However, studies in Jurkat T-lymphocytes suggest that calcineurin-regulated Mef2 activation requires recruitment of NFATc2 (Blaeser et al. 2000; Youn et al. 2000) . In the mouse heart, the major pathway appears to be NFAT since expressing dominant negative Mef2 rescued only cardiac dilation and not hypertrophy (Van Oort et al. 2006) . In the same mouse study, overexpressing Mef2 induced a cardiac dilation phenotype without hypertrophy, suggesting that Mef2 mainly contributes to the dilation phenotype induced by calcineurin. Interestingly, flies expressing tinC-Gal4 . UASMef2 had significantly increased end-diastolic dimensions ( Figure S7 ), similar to the tinC-CanA act phenotype, although the flies overexpressing Mef2 did not display reduced fractional shortening, suggesting that Mef2 is necessary but not sufficient for calcineurin-induced reduction in contractility. These results suggest that an NFAT-independent pathway through Mef2 in Drosophila may regulate cardiac enlargement and that additional factors outside of Mef2 may be involved in controlling cardiac function.
Several potential genes were excluded as modifiers from our original candidate region. The Doc genes are known to regulate Drosophila cardiac development (Reim and Frasch 2005) , and we showed that knocking down Doc expression with RNAi caused cardiac enlargement and did not rescue tinC-CanA act . This implies that Doc genes are important for cardiac development but we do not have evidence for them regulating calcineurin. Argk has high expression in the adult Drosophila heart. Argk is an enzyme that transfers the phosphate on ATP to arginine, creating an energy-rich buffer for maintaining ATP concentration (Newsholme et al. 1978) . Although it is conceivable that Argk functions to provide sufficient energy for the fly myocardium, our results showed that disrupting Argk with a transposable element did not produce a phenotype and did not rescue calcineurin-induced cardiac enlargement. These results suggest that Argk does not regulate calcineurin-induced cardiac enlargement. However, we note that the gene expression was decreased by only 30% in the heterozygous PBac{PB}Argk f05255 line used ( Figure S6C ) and it is possible that the lack of rescue was due to incomplete knockdown of gene expression. A deficiency encompassing Galk suppressed the CanA actinduced phenotypes in heart and posterior wing. However, this deficiency did not suppress phenotypes driven by ubiquitous Act5C-Gal4, ectodermal dpp-Gal4, or mesodermal Mef2-Gal4 drivers. These observations could be explained by the tissue-specific context in which calcineurin was expressed. The expression of each driver occurs in different tissues. Although e16E-Gal4 and dpp-Gal4 expression of CanA act induced wing phenotypes, e16E-Gal4 drives expression in the posterior wing while dpp-Gal4 drives expression anterior to the anterior-posterior boundary during imaginal disc development at the third instar larva stage (Brower 1986; de Celis 1997) . Many signaling factors are differentially expressed during wing development in these two separate compartments to guide correct patterning. For example, engrailed and hedgehog are expressed posteriorly, guiding formation of the posterior wing veins (Brower 1986; Lee et al. 1992) , while dpp and the EGFR inhibitor knot are expressed specifically in the anterior wing imaginal disc (de Celis 1997; Mohler et al. 2000) . It is possible that Galk modification of calcineurin signaling is regulated by these differentially expressed factors. In addition, Act5C-Gal4 and Mef2-Gal4 driving CanA act induced lethality that was not suppressed by deficiency of Galk. These drivers induce transcript expression in multiple tissues during early embryonic development (Burn et al. 1989; . One explanation for the findings is that the signals at an early stage of development involve pathways that are not modulated by Galk.
We examined the survival of tinC-CanA act Drosophila and in the context of the insertion Mi{ET1}Galk MB10638 . Of note, in mice, cardiac-specific expression of CanA act also induced premature sudden death (Molkentin et al. 1998) . Flies heterozygously expressing tinC-CanA act had a significantly reduced life span compared to the control group. This reduction was suppressed in the context of one copy of Mi{ET1}Galk MB10638 ( Figure S4 ), further suggesting that deficiency in Galk suppresses multiple cardiac calcineurin-induced phenotypes. However, a caveat to the interpretation of this experiment is the possibility of genetic background confounding the beneficial effects seen by disruption of Galk.
Galactokinase belongs to the GHMP ATP-dependent kinase family (named after the four representative kinases in this family: galactokinase, homoserine kinase, mevalonate kinase, and phosphomevalonate kinase) (Holden et al. 2004) . In the fly, galactokinase phosphorylates galactose and N-acetyl-galactosamine (GalNAc), allowing further utilization in either metabolism (energy production) or glycosylation (protein modification) (Holden et al. 2004) . These pathways potentially lead to cardiac enlargement: either galactokinase promotes a higher level of phosphorylated galactose, galactose-1-p, leading to a diseased state, or downstream reactions involving UDP-galactose incorporation into glycosylated proteins promote cardiac enlargement, or both mechanisms may be required. A previous screen examining Drosophila cardiac development discovered that mutations in HMG-CoA reductase (the rate-limiting enzyme in the mevalonate pathway) induce a cardiac phenotype by Figure 6 The deficiency Df(3L)ED4416 did not rescue Act5C-Gal4 . UAS-YCanA act -induced lethality, dpp-Gal4 . UAS-YCanA act -induced unexpanded wing, or Mef2-Gal4 . UAS-YCanA act -induced pupal lethality. (A) Progeny number from the cross Act5C-Gal4/CyO 3 UAS-YCanA act /CyO;Df(3L)ED4416/ TM2. Driving UAS-YCanA act with an actin (Act5C-Gal4) driver resulted in a lethal phenotype, which was not rescued by Df(3L)ED4416. (B) Percentage of total abnormal-winged progeny from the cross dpp-Gal4/TM6B 3 UAS-YCanA act /CyO;Df(3L)ED4416/TM2. Expressing CanA act with a dpp driver resulted in a shriveled abnormal wing phenotype. This was not rescued by Df(3L)ED4416. (C) Total progeny from the cross Mef2-Gal4 3 UAS-YCanA act /CyO;Df (3L)ED4416/MKRS or Mef2-Gal4 3 UAS-YCanA act /CyO;Mi{ET1}Galk MB10638 /MKRS. Expressing CanA act with a Mef2-driver resulted in a pupal lethal phenotype that was not rescued by Df(3L)ED4416 or Mi{ET1}Galk MB10638 . Data were analyzed using Fisher's exact test.
geranylgeranylation of the G-protein Gg1, suggesting a pathway by which post-translational modifications can alter the fly heart (Yi et al. 2006) .
In additional experiments, we show that a transposable element insertion in galectin (a galactoside-binding lectin) suppressed the tinC-CanA act cardiac phenotype ( Figure S8 , A and B). Mammalian Galectin3 has been shown to bind to Galk-regulated N-acetyllactosamine side chains on EGFR, preventing endocytosis and enhancing signaling of isolated mouse mammary cells (Partridge et al. 2004) . Driving activated EGFR in the Drosophila heart has been shown to induce a cardiac hypertrophy phenotype (Yu et al. 2013 ) and sprouty, a regulator of EGFR signaling, has been shown to modify calcineurin-induced rough eye (Sullivan and Rubin 2002) . Although speculation, one potential mechanism by which galactokinase functions to modulate calcineurininduced cardiac enlargement is by influencing cotranslational glycosylation of EGFR or another yet unidentified cell surface protein that is bound by galectin ( Figure S8C) .
A yeast homolog of Galk, Gal3p, has been found to act as a transcriptional activator by interacting with Gal80p (Zenke et al. 1996) ; transcriptional regulation is activated with the binding of galactose and ATP to Gal3p. This suggests the possibility that Galk may act as a modifier of transcription for known pathways including Mef2. Whether Galk functions as part of the transcriptional machinery remains to be determined.
In conclusion, we have developed a model for screening for novel modifiers of constitutively active calcineurin in the Drosophila heart and identified galactokinase as a novel modifier of constitutively active calcineurin-induced cardiomyopathy, shortened life span, and wing vein abnormality in adult Drosophila. These findings have set up a system for delineating the pathways involved in CanA act -induced cardiomyopathy in Drosophila.
Yin, Z., X. L. Xu, and M. Frasch, 1997 Regulation of the twist target gene tinman by modular cis-regulatory elements during early mesoderm development. according to standard procedures as previously described (ALAYARI et al. 2009; YU et al. 2010) using 5% BSA in TBS as the blocking reagent with a rabbit αGFP antibody (Invitrogen, Inc.), and Alexa Fluor488 goat αrabbit secondary antibody (Invitrogen, Inc.). After immuno--staining, the Drosophila heart was visualized under a Zeiss LSM510 confocal microscope. Consecutive Z--stacks were taken at 1µm intervals, and projected to form a 3D image in the LSM image browser software.
Cardiac cell number
Fly hearts expressing tinC--nuclear RFP in the presence of either tinC--GFP or tinC--YCanA act were imaged with confocal microscopy. Ostia cells (Os) along with the cuticle pattern mark the boundaries to abdominal compartments (A1--A3). tinC--GFP or tinC--YCanA act flies were crossed with tinC--Gal4, UAS--nuclear RFP flies and the offspring were collected 1--2 days after eclosion.
Hearts were exposed by dissection as previously described for confocal microscopy and imaged without staining under the confocal microscope (OCORR et al. 2007; YU et al. 2010) . Nuclei from visualization of RFP were counted to represent the number of cardiomyocytes present in each heart.
Life span
Drosophila were collected 1--2 days after eclosion. 10 males and 10 females were kept in the same vial and food changed every 2--3 days. A total of 6 vials were monitored for every
